Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Request a free trial

No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: CANCIDAS

« Back to Dashboard
Cancidas is a drug marketed by Merck and is included in one NDA. It is available from one supplier. There are three patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in CANCIDAS is caspofungin acetate. There are six drug master file entries for this compound. One supplier is listed for this compound. There is one tentative approval for this compound. Additional details are available on the caspofungin acetate profile page.

Summary for Tradename: CANCIDAS

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2

Pharmacology for Tradename: CANCIDAS

Ingredient-typeLipopeptides
Drug ClassEchinocandin Antifungal

Clinical Trials for: CANCIDAS

Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates
Status: Completed Condition: Invasive Fungal Infection

Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
Status: Completed Condition: Invasive Aspergillosis

Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)
Status: Completed Condition: Fungal Infection

Pharmacokinetic, Safety and Efficacy of Intermittent Application of Caspofungin for Antifungal Prophylaxis
Status: Completed Condition: Fungal Infection

Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)
Status: Terminated Condition: Invasive Candidiasis

Pharmacokinetics of Caspofungin in Burn Patients
Status: Completed Condition: Thermal Injury

Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit
Status: Enrolling by invitation Condition: Invasive Fungal Infection

Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure
Status: Recruiting Condition: Bacterial Infections and Mycoses; Liver Disease

Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease
Status: Recruiting Condition: Invasive Pulmonary Aspergillosis; Chronic Obstructive Pulmonary Disease

Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
Status: Recruiting Condition: Fungal Infection; Hematopoietic/Lymphoid Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
CANCIDAS
caspofungin acetate
INJECTABLE;IV (INFUSION)021227-001Jan 26, 2001RXYes6,136,783*PED<disabled>Y<disabled>
Merck
CANCIDAS
caspofungin acetate
INJECTABLE;IV (INFUSION)021227-002Jan 26, 2001RXYes6,136,783*PED<disabled>Y<disabled>
Merck
CANCIDAS
caspofungin acetate
INJECTABLE;IV (INFUSION)021227-001Jan 26, 2001RXYes5,952,300*PED<disabled>Y<disabled>
Merck
CANCIDAS
caspofungin acetate
INJECTABLE;IV (INFUSION)021227-001Jan 26, 2001RXYes5,514,650*PED<disabled>Y<disabled>
Merck
CANCIDAS
caspofungin acetate
INJECTABLE;IV (INFUSION)021227-002Jan 26, 2001RXYes5,514,650*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CANCIDAS

Drugname Dosage Strength RLD Submissiondate
caspofungin acetateFor Injection50 mg/vial and 70 mg/vialCancidas6/26/2009

Non-Orange Book Patents for Tradename: CANCIDAS

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,378,804 Aza cyclohexapeptide compounds<disabled in preview>
5,792,746 Aza cyclohexapeptide compounds<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc